ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.600
0.00 (0.00%)
At close: Dec 20, 2024, 4:00 PM
1.610
+0.010 (0.63%)
After-hours: Dec 20, 2024, 5:54 PM EST
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | David Parkinson |
Contact Details
Address: 999 West Broadway, Suite 720 Vancouver, BC V5Z 1K5 Canada | |
| Phone | (778) 331-0962 |
| Website | essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer and Director |
| David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Peter A. Virsik M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer and Executive Vice President |
| Chandtip Chandhasin | Executive |
| Erica Osbourne | Executive |
| Erin Rudsinski | Executive |
| Loleta Harris | Executive |
| Neil Thapar | Executive |
| Nkengyal Barber | Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 10-K | Annual Report |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | 8-K | Current Report |